Exagen Q2 revenue $17.2M (+14% YoY); net loss widens to $4.4M; FY guidance $65-70M

EXAGEN INC.

2025-Q2 EPS reported -$0.41 revenue$32,700,000

Revenue $17.2M, 14% YoY growth; AVISE CTD test volume +7% YoY, +14% QoQ; gross margin 60.4%.
Net loss $4.4M vs $3.0M in Q2 2024; operating loss $2.6M, roughly flat; adjusted EBITDA -$1.7M.
Cash $30.0M after $20.2M public offering and new credit facility; ASP $428, up $27 YoY.
FY 2025 revenue guidance $65M-$70M; expects positive adjusted EBITDA in Q4 at high end.
Appointed Dr. Michael Mahler as CSO; added Chas McKhann to board of directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.